Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

Blood

Volumn 127, Issue 3, 2016, Pages 325-332

  Milosevic Feenstra, Jelena D ^a   Nivarthi, Harini ^a   Gisslinger, Heinz ^b   Leroy, Emilie ^c,d   Rumi, Elisa ^e   Chachoua, Ilyas ^c,d   Bagienski, Klaudia ^a   Kubesova, Blanka ^a,f   Pietra, Daniela ^e   Gisslinger, Bettina ^b   Milanesi, Chiara ^e   Ager, Roland J ^a   Chen, Doris ^a   Berg, Tiina ^a   Schalling, Martin ^b   Schuster, Michael ^a   Bock, Christoph ^a   Constantinescu, Stefan N ^c,d   Cazzola, Mario ^e,g   Kralovics, Robert ^a,b  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d DE DUVE INSTITUTE   (Belgium)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f MASARYK UNIVERSITY   (Czech Republic)

^g UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; THROMBOPOIETIN RECEPTOR; MPL PROTEIN, HUMAN;

ARTICLE; CHROMOSOME ABERRATION; CLONAL VARIATION; CONTROLLED STUDY; EXOME; EXON; FEMALE; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC VARIABILITY; GERMLINE MUTATION; HEMATOPOIESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; SOMATIC MUTATION; THROMBOCYTHEMIA; WHOLE EXOME SEQUENCING; COPY NUMBER VARIATION; DNA MUTATIONAL ANALYSIS; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MUTATION; MYELOPROLIFERATIVE DISORDER; PROCEDURES; X CHROMOSOME INACTIVATION;

DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; EXOME; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; PRIMARY MYELOFIBROSIS; RECEPTORS, THROMBOPOIETIN; THROMBOCYTHEMIA, ESSENTIAL; X CHROMOSOME INACTIVATION;

EID: 84958213572     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-07-661835     Document Type: Article

References (35)

1. Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
2. James C, Ugo V, Le Coúedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
5. Etheridge SL, Cosgrove ME, Sangkhae V, et al. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood. 2014;123(7):1059-1068.
6. Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med. 2012; 366(10):967-969.
7. Rumi E, Harutyunyan AS, Casetti I, et al. A novel germline JAK2 mutation in familial myeloproliferative neoplasms. Am J Hematol. 2014;89(1):117-118.
8. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
9. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405.
10. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
11. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood. 2006; 108(10):3472-3476.
12. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood. 2008;112(1):141-149.
13. Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembranecytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107(5):1864-1871.
14. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198-4200.
15. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2):447-452.
16. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
17. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-6192.
18. Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012;119(19): 4480-4485.
19. Swerdlow S, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
20. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
21. Milosevic JD, Puda A, Malcovati L, et al. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol. 2012; 87(11):1010-1016.
22. Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114(17): 3538-3545.
23. Defour JP, Itaya M, Gryshkova V, et al. Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proc Natl Acad Sci USA. 2013;110(7):2540-2545.
24. Kawamata N, Ogawa S, Yamamoto G, et al. Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Exp Hematol. 2008;36(11): 1471-1479.
25. Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol. 2007;35(11):1641-1646.
26. Hitchcock IS, Chen MM, King JR, Kaushansky K. YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood. 2008; 112(6):2222-2231.
27. Harutyunyan AS, Kralovics R. Role of germline genetic factors in MPN pathogenesis. Hematol Oncol Clin North Am. 2012;26(5):1037-1051.
28. Lambert MP, Jiang J, Batra V, Wu C, Tong W. A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia. Am J Hematol. 2012;87(5): 532-534.
29. El-Harith HA, Roesl C, Ballmaier M, et al. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol. 2009;144(2):185-194.
30. Feese MD, Tamada T, Kato Y, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci USA. 2004;101(7):1816-1821.
31. Chen WM, Yu B, Zhang Q, Xu P. Identification of the residues in the extracellular domain of thrombopoietin receptor involved in the binding of thrombopoietin and a nuclear distribution protein (human NUDC). J Biol Chem. 2010;285(34): 26697-26709.
32. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472-1477.
33. Panovska-Stavridis I, Eftimov A, Pivkova-Veljanovska A, Ivanovski M, Cevreska L, Dimovski AJ. Familiar JAK2 G571S variant not linked with essential trombocythemia [abstract]. Blood. 2014;124(21):5585.
34. Campregher PV, Helman R, Pereira WO, et al. Genomic profile of patients with triple negative (JAK2, CALR and MPL) essential thrombocythemia and primary myelofibrosis [abstract]. Blood. 2014;124(21). Abstract 4589.
35. Cabagnols X, Ianotto JC, Bluteau O, et al. Mutational profile in essential thrombocytemia (Et) "negative" for Jak2 and Mpl [abstract]. Haematologica. 2014;99(6)(suppl 1):515. Abstract 1328.